Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 54.41B | 54.53B | 54.35B | 53.26B | 51.72B |
| Total Other Revenue | 2.17B | 2.14B | 2.02B | 1.92B | 1.50B |
| Total Revenue | 56.58B | 56.67B | 56.37B | 55.19B | 53.22B |
| Cost of Revenue | 13.83B | 13.62B | 13.39B | 13.09B | 12.95B |
| Gross Profit | 42.74B | 43.05B | 42.98B | 42.09B | 40.28B |
| SG&A Expenses | 13.32B | 13.24B | 13.30B | 13.13B | 12.78B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 298.00M | 521.00M | -559.00M | 149.00M | 409.00M |
| Total Operating Expenses | 38.55B | 38.07B | 36.31B | 36.08B | 35.59B |
| Operating Income | 18.03B | 18.61B | 20.06B | 19.11B | 17.63B |
| Income Before Tax | 15.78B | 16.35B | 16.42B | 15.61B | 14.92B |
| Income Tax Expenses | 2.27B | 2.39B | 2.04B | 1.97B | 2.06B |
| Earnings from Continuing Operations | 13.51K | 13.97K | 14.38K | 13.64K | 12.86K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 20.00M | 17.00M | 10.00M | 16.00M | -1.00M |
| Net Income | 13.53B | 13.98B | 14.39B | 13.65B | 12.86B |
| EBIT | 18.03B | 18.61B | 20.06B | 19.11B | 17.63B |
| EBITDA | 22.53B | 23.08B | 24.53B | 23.48B | 21.96B |
| EPS Basic | 7.03 | 7.21 | 7.36 | 6.91 | 6.43 |
| Normalized Basic EPS | 5.44 | 5.61 | 6.13 | 5.79 | 5.30 |
| EPS Diluted | 6.98 | 7.15 | 7.31 | 6.86 | 6.39 |
| Normalized Diluted EPS | 5.40 | 5.57 | 6.09 | 5.75 | 5.27 |
| Average Basic Shares Outstanding | 7.70B | 7.76B | 7.83B | 7.92B | 8.00B |
| Average Diluted Shares Outstanding | 7.75B | 7.81B | 7.88B | 7.97B | 8.06B |
| Dividend Per Share | 4.67 | 4.67 | 3.86 | 3.86 | 3.86 |
| Payout Ratio | 64.15% | 55.91% | 54.32% | 57.26% | 60.27% |